Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Merestinib

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Merestinib: Patents, clinical trial progress, indications

Merestinib is an investigational drug.

There have been 8 clinical trials for Merestinib. The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2016.

The most common disease conditions in clinical trials are Neoplasm Metastasis, Neoplasms, and Neoplasms, Second Primary. The leading clinical trial sponsors are Eli Lilly and Company, University of Utah, and Jacqueline Garcia, MD.

There are four US patents protecting this investigational drug and fifty-one international patents.

Recent Clinical Trials for Merestinib
Merestinib on Bone Metastases in Subjects With Breast CancerEli Lilly and CompanyPhase 1
Merestinib on Bone Metastases in Subjects With Breast CancerUniversity of UtahPhase 1
Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaEli Lilly and CompanyPhase 1

See all Merestinib clinical trials

Clinical Trial Summary for Merestinib

Top disease conditions for Merestinib
Top clinical trial sponsors for Merestinib

See all Merestinib clinical trials

US Patents for Merestinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Merestinib   See Pricing Methods of treating a neuroendocrine tumor SCRIPPS HEALTH (San Diego, CA)   See Pricing
Merestinib   See Pricing Amidophenoxyindazoles useful as inhibitors of c-Met Eli Lilly and Company (Indianapolis, IN)   See Pricing
Merestinib   See Pricing Anti-c-Met antibodies Eli Lilly and Company (Indianapolis, IN)   See Pricing
Merestinib   See Pricing Anti-c-met antibodies Eli Lilly and Company (Indianapolis, IN)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Merestinib

Drugname Country Document Number Estimated Expiration Related US Patent
Merestinib World Intellectual Property Organization (WIPO) 2019040497 2037-08-22   See Pricing
Merestinib Argentina 074632 2028-07-24   See Pricing
Merestinib Austria 546444 2028-07-24   See Pricing
Merestinib Australia 2009274256 2028-07-24   See Pricing
Merestinib Canada 2731773 2028-07-24   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.